3 270

Cited 6 times in

Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author류한작-
dc.contributor.author박준용-
dc.contributor.author손창영-
dc.contributor.author안상훈-
dc.contributor.author이명하-
dc.contributor.author이중민-
dc.contributor.author전재윤-
dc.contributor.author한광협-
dc.date.accessioned2014-12-19T17:26:32Z-
dc.date.available2014-12-19T17:26:32Z-
dc.date.issued2012-
dc.identifier.issn1478-3223-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/91415-
dc.description.abstractBACKGROUND AND AIMS: Few studies have adequately examined the efficacy of lamivudine plus adefovir (LAM+ADV) combination therapy vs. entecavir (ETV) monotherapy in HBeAg-positive hepatitis B patients who fail to respond to sequential treatment with LAM and ADV. We compared directly the efficacy of LAM+ADV vs. ETV in such patients and assessed prognostic factors associated with a virologic response at month 12. METHODS: In total, 72 HBeAg-positive patients who showed resistance (n = 33) or a suboptimal virologic response (n = 39) to ADV monotherapy with resistance to LAM therapy underwent rescue therapy (31 LAM+ADV and 41 ETV). All patients were followed for at least 12 months. RESULTS: Following 12 months of treatment, in the LAM+ADV and ETV groups, a virologic response was observed in 7/31 (22.6%) and 8/41 (19.5%; P = 0.777) patients; ALT normalization occurred in 11/13 (84.6%) and 16/18 (88.9%; P = 0.566); HBeAg seroconversion in 1/31 (2.3%) and 4/41 (9.8%; P = 0.341) and a virologic breakthrough in 3/31 (9.0%) and 5/41 (12.1%; P = 0.452) respectively. Independent prognostic factors associated with a virologic response were the baseline HBV-DNA level (OR = 0.37; 95% CI 0.17-0.80; P = 0.011) and the duration of prior ADV monotherapy (OR = 0.89; 95% CI 0.83-0.95; P = 0.044). CONCLUSIONS: Neither LAM+ADV nor ETV was adequately effective in patients with sequential LAM and ADV treatment failure. Thus, when chronic hepatitis B patients show resistance or suboptimal response to ADV monotherapy, early modification of treatment should be considered.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfLiver International-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenine/analogs & derivatives*-
dc.subject.MESHAdenine/therapeutic use-
dc.subject.MESHAdult-
dc.subject.MESHAlanine Transaminase/blood-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHDNA, Viral/blood-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHGuanine/analogs & derivatives*-
dc.subject.MESHGuanine/therapeutic use-
dc.subject.MESHHepatitis B/drug therapy*-
dc.subject.MESHHepatitis B e Antigens/analysis-
dc.subject.MESHHepatitis B e Antigens/metabolism*-
dc.subject.MESHHepatitis B, Chronic/drug therapy-
dc.subject.MESHHepatitis B, Chronic/virology-
dc.subject.MESHHumans-
dc.subject.MESHLamivudine/therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganophosphonates/therapeutic use*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Failure-
dc.titleLamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorChang Young Son-
dc.contributor.googleauthorHan Jak Ryu-
dc.contributor.googleauthorJung Min Lee-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorMyoung Ha Lee-
dc.contributor.googleauthorKwang Hyub Han-
dc.contributor.googleauthorChae Yoon Chon-
dc.contributor.googleauthorJun Yong Park-
dc.identifier.doi22452737-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01334-
dc.contributor.localIdA01675-
dc.contributor.localIdA01997-
dc.contributor.localIdA02226-
dc.contributor.localIdA02758-
dc.contributor.localIdA04268-
dc.contributor.localIdA03184-
dc.contributor.localIdA03544-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ02171-
dc.identifier.pmid22452737-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02793.x/abstract-
dc.subject.keywordadefovir-
dc.subject.keywordentecavir-
dc.subject.keyword(HBeAg-positive)chronic hepatitis B-
dc.subject.keywordlamivudine-
dc.subject.keywordsequentialtherapy-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameRyu, Han Jak-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameSon, Chang Young-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Myoung Ha-
dc.contributor.alternativeNameLee, Jung Min-
dc.contributor.alternativeNameChon, Chae Yoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorRyu, Han Jak-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorSon, Chang Young-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Myoung Ha-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorLee, Jung Min-
dc.contributor.affiliatedAuthorChon, Chae Yoon-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.volume32-
dc.citation.number7-
dc.citation.startPage1179-
dc.citation.endPage1185-
dc.identifier.bibliographicCitationLiver International, Vol.32(7) : 1179-1185, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.